Harbin Gloria Pharmaceuticals Asset Resilience Ratio
Harbin Gloria Pharmaceuticals asset resilience ratio. Harbin Gloria Pharmaceuticals (002437) has an Asset Resilience Ratio of 9.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002437 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Harbin Gloria Pharmaceuticals (2012–2025)
Asset resilience ratio of Harbin Gloria Pharmaceuticals from 2012 to 2025. This chart shows how Harbin Gloria Pharmaceuticals's Asset Resilience Ratio has changed over time. Read Harbin Gloria Pharmaceuticals debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Harbin Gloria Pharmaceuticals's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Harbin Gloria Pharmaceuticals (002437) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥284.08 Million | 9.04% |
| Total Liquid Assets | CN¥284.08 Million | 9.04% |
Asset Resilience Insights
- Limited Liquidity: Harbin Gloria Pharmaceuticals maintains only 9.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Harbin Gloria Pharmaceuticals Industry Peers by Asset Resilience Ratio
Compare Harbin Gloria Pharmaceuticals's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Harbin Gloria Pharmaceuticals Asset Resilience Ratio by Year (2012–2025)
Harbin Gloria Pharmaceuticals asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Harbin Gloria Pharmaceuticals.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.02% | CN¥533.66 Million ≈ $78.09 Million |
CN¥3.13 Billion ≈ $458.69 Million |
+15.96pp |
| 2024-12-31 | 1.06% | CN¥30.00 Million ≈ $4.39 Million |
CN¥2.83 Billion ≈ $413.40 Million |
-0.18pp |
| 2022-12-31 | 1.24% | CN¥50.56 Million ≈ $7.40 Million |
CN¥4.07 Billion ≈ $596.18 Million |
-7.93pp |
| 2013-12-31 | 9.17% | CN¥270.00 Million ≈ $39.51 Million |
CN¥2.94 Billion ≈ $430.65 Million |
+6.05pp |
| 2012-12-31 | 3.12% | CN¥80.00 Million ≈ $11.71 Million |
CN¥2.56 Billion ≈ $375.28 Million |
-- |
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more